Close

MUC1

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Product List Background Anti-MUC1 CAR-T Services Anti-MUC1 CAR-T In Vitro Assay ServicesAnti-MUC1 CAR-T In Vivo Assay Services

Product List

Creative Biolabs provides various Anti-MUC1-related products to support global customers’ projects, please feel free to contact us for further communication.

Background

MUC1 is a glycoprotein with extensive O-linked glycosylation of its extracellular domain. It is overexpressed in a variety of epithelial cancers and plays a crucial role in the progression of the disease. Tumor-associated MUC1 differs from the MUC1 expressed in normal cells with regard to its biochemical features, cellular distribution, and function. Based on these features of MUC1 between normal and tumor cells, MUC1 has been investigated as one of the hot targets for antibody and engineering CAR T cells for cancer therapy.

Schematic representation of the recognition of different domains by different antibodies. Fig.1 Schematic representation of the recognition of different domains by different antibodies.1

Associated Disease

Lung cancer

Pancreas cancer

Breast cancer

MUC1-expressing tumors

Viral infection

Others

Anti-MUC1 CAR-T Services

Anti-MUC1 CAR-T In Vitro Assays

Anti-MUC1 CAR-T Expression Test

For CART research, Creative Biolabs is dedicated to providing several innovative CAR detection reagents for CAR expression validation. Meanwhile, we also provide a comprehensive range of assay services to support your CART projects. For example, validation of anti-MUC1 CAR expression by flow cytometry is usually a classical assay format in MUC1 CAR therapy projects, providing a lot of intuitive information to clients.

Anti-MUC1 CAR expression evaluation in transduced human T cells by FACS analysis of Myc-tag expression. Anti-MUC1 CAR cells were gated by CD4 or CD8 channel, and then detected Myc-tag expression.. Fig.2 Anti-MUC1 CAR expression evaluation in transduced human T cells by FACS analysis of Myc-tag expression. Anti-MUC1 CAR cells were gated by CD4 or CD8 channel, and then detected Myc-tag expression.2

Anti-MUC1 CAR-T Cytokine Release Test

The cytokine release test is a valuable assay in CART validation and characterization, which provides valuable insights into the activated and lytic phenotype of CAR T cells. Common types of cytokine tests include IFN-γ, TNF-α, IL-2, Granzyme B, along with many other cytokines. Creative Biolabs specializes in providing comprehensive cytokine release test services for global clients by many approaches, including ELISA, CBA, and FACS staining intracellularly.

IFN-γ and Granzyme B secretion detection of anti-MUC1 CAR-T cells co-cultured with tMUC1high HCC70 cells by FACS staining intracellularly for IFN-γ and Granzyme B. (Zhou, et al., 2019). Fig.3 IFN-γ and Granzyme B secretion detection of anti-MUC1 CAR-T cells co-cultured with tMUC1high HCC70 cells by FACS staining intracellularly for IFN-γ and Granzyme B.2

Cytokines panel detection of anti-MUC1 CAR-T cells co-cultured with tMUC1high HCC70 cells at E:T ratio of 2:1 by human cytokine array. (Zhou, et al., 2019) Fig.4 Cytokines panel detection of anti-MUC1 CAR-T cells co-cultured with tMUC1high HCC70 cells at E:T ratio of 2:1 by human cytokine array.2

Anti-MUC1 CAR-T In Vitro Cytotoxicity Assay

CAR T cell-mediated tumor-killing test is an important indicator for CART research. Creative Biolabs offers in vitro cytotoxicity assay services to support the evaluation of anti-MUC1 CAR-T cell therapy by various approaches, such as radioactive chromium release method, bioluminescence method, and flow cytometry method. In the testing service, we will optimize the experimental conditions according to customers' special needs to get more desirable data results.

In vitro cytotoxicity activity of anti-MUC1 CAR-T cells against TNBC tumor cells. (Zhou, et al., 2019) Fig.5 In vitro cytotoxicity activity of anti-MUC1 CAR-T cells against TNBC tumor cells. (A) tMUC1 expression validation of several TNBC cell lines by flow cytometry. (B) In vitro cytotoxicity validation of MUC1 CAR T cells against TNBC tumor cell at E:T ratio of 5:1 for 3 days' co-culture.2

Anti-MUC1 CAR-T In Vivo Assays

Efficacy Test of Anti-MUC1 CAR-T

For in vivo tumor killing analysis, Creative Biolabs provides many optimized mouse models and various detection solutions to speed clients' CART research. At the same time, our in vivo services also cover a variety of phenotypic analyses on cells.

In vivo anti-tumor validation of MUC1 CAR-T cells against HCC70 tumor cells. (Zhou, et al., 2019) Fig.6 In vivo anti-tumor validation of MUC1 CAR-T cells against HCC70 tumor cells. (A) Anti-MUC1 CAR-T cells inhibit HCC70 tumor growth in NSG mice by a single injection in vivo. (B) Tumor weight analysis of resected tumor mass on day 57 at endpoint.2

Toxicity Evaluation Anti-MUC1 CAR-T

In addition, Creative Biolabs also provides comprehensive solutions for the toxicity assessment of CAR-T cells to ensure the safety and efficacy of the CART cells, such as on-target toxicity assessment, and off-target toxicity assessment.

For more MU1 CAR-T related assays, please don't hesitate to contact us directly.

References

  1. Bose, Mukulika, and Pinku Mukherjee. "Potential of anti-MUC1 antibodies as a targeted therapy for gastrointestinal cancers." Vaccines 8.4 (2020): 659.
  2. Zhou, Ru.; et al. "CAR T cells targeting the tumor MUC1 glycoprotein reduce triple-negative breast cancer growth." Frontiers in immunology 10 (2019): 1149.
  • CAR Vector Products

  • TCR Vector Products

  • AbTCR Vector Products

  • CAR Cell Products

  • CAR Viral Particles

  • DMAb

  • Protein

  • TriCAR Vector Products

  • TCR-Like CAR

  • CAR-MA Vector Products

  • CAR-MA Cell Products

  • CAR Animal Cells

  • CAR mRNA

Loading...
  • Target Species:
  • Antibody Clone:
  • Antibody Host:
  • Receptor Construction:
  • Vector Type:
  • Targeting Cell Type:
  • CAR Vector Type:
CAT Product Name Target Species Antibody Clone Antibody Host Receptor Construction Vector Type Targeting Cell Type CAR Vector Type Inquiry & Datasheet
CAR-WJ3381 Anti-MUC1 (CBWJC-4199) h(CD28-CD3ζ) CAR, pCDCAR1 Human CBWJC-4199 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-WJ3382 Anti-MUC1 (CBWJC-4200) h(CD28-CD3ζ) CAR, pCDCAR1 Human CBWJC-4200 Rabbit scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-WJ3383 Anti-MUC1 (CBWJC-4201) h(CD28-CD3ζ) CAR, pCDCAR1 Human CBWJC-4201 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-WJ3384 Anti-MUC1 (CBWJC-4202) h(CD28-CD3ζ) CAR, pCDCAR1 Human CBWJC-4202 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-WJ3385 Anti-MUC1 (CBWJC-4203) h(CD28-CD3ζ) CAR, pCDCAR1 Human CBWJC-4203 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-WJ3386 Anti-MUC1 (CBWJC-4204) h(CD28-CD3ζ) CAR, pCDCAR1 Human CBWJC-4204 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-WJ3387 Anti-MUC1 (CBWJC-4205) h(CD28-CD3ζ) CAR, pCDCAR1 Human CBWJC-4205 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-WJ3388 Anti-MUC1 (CBWJC-4206) h(CD28-CD3ζ) CAR, pCDCAR1 Human CBWJC-4206 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-WJ3389 Anti-MUC1 (CBWJC-4207) h(CD28-CD3ζ) CAR, pCDCAR1 0 CBWJC-4207 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-WJ3390 Anti-MUC1 (CBWJC-4208) h(CD28-CD3ζ) CAR, pCDCAR1 Human CBWJC-4208 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-YF251 Anti-MUC1 (CBL-YF066) h(4-1BB-CD3ζ) CAR, pCDCAR1 Human CBL-YF066 Humanized scFv-4-1BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-0120ZP3407 Anti-MUC1 (Clivatuzumab) h(CD28-CD3ζ) CAR, pCDCAR1 Human Clivatuzumab Humanized scFv-CD28-CD3ζ Lentiviral vector T Cell   Add to Cart   Datasheet
CAR-0120ZP3427 Anti-MUC1 (4G5) h(CD28-CD3ζ) CAR, pCDCAR1 Human 4G5 Mouse scFv-CD28-CD3ζ Lentiviral vector T Cell   Add to Cart   Datasheet
CAR-0120ZP3428 Anti-MUC1 (4G5) h(4-1BB-CD3ζ) CAR, pCDCAR1 Human 4G5 Mouse scFv-4-1BB-CD3ζ Lentiviral vector T Cell   Add to Cart   Datasheet
CAR-0120ZP3429 Anti-MUC1 (7B8) h(CD28-CD3ζ) CAR, pCDCAR1 Human 7B8 Mouse scFv-CD28-CD3ζ Lentiviral vector T Cell   Add to Cart   Datasheet
CAR-0120ZP3430 Anti-MUC1 (7B8) h(4-1BB-CD3ζ) CAR, pCDCAR1 Human 7B8 Mouse scFv-4-1BB-CD3ζ Lentiviral vector T Cell   Add to Cart   Datasheet
CAR-0120ZP3433 Anti-MUC1 (DMB5F3) h(CD28-CD3ζ) CAR, pCDCAR1 Human DMB5F3 Humanized scFv-CD28-CD3ζ Lentiviral vector T Cell   Add to Cart   Datasheet
CAR-0120ZP3434 Anti-MUC1 (DMB5F3) h(4-1BB-CD3ζ) CAR, pCDCAR1 Human DMB5F3 Humanized scFv-4-1BB-CD3ζ Lentiviral vector T Cell   Add to Cart   Datasheet
CAR-0120ZP3435 Anti-MUC1 (H23) h(CD28-CD3ζ) CAR, pCDCAR1 Human H23 Mouse scFv-CD28-CD3ζ Lentiviral vector T Cell   Add to Cart   Datasheet
CAR-0120ZP3436 Anti-MUC1 (H23) h(4-1BB-CD3ζ) CAR, pCDCAR1 Human H23 Mouse scFv-4-1BB-CD3ζ Lentiviral vector T Cell   Add to Cart   Datasheet
XS-0823-LX79 Anti-hMUC1 (M3) ICD(CD28-OX40-CD3ζ) CAR-MA, pAd5f35 Vector Human M3 Adenoviral vectors   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.